Novo Nordisk Navigates a Tightrope of Price Cuts and Patent Erosion as GLP-1 Competition Intensifies

Novo Nordisk cuts Wegovy prices in Portugal by 19% while Brazil approves first generic Ozempic rival, reflecting twin challenges to GLP-1 franchise.

Novo Nordisk is confronting a twin challenge that cuts to the heart of its GLP-1 franchise: at one end, a voluntary price reduction on Wegovy in Portugal to boost patient access, and at the other, the first homegrown rival to Ozempic winning approval in Brazil. The Danish drugmaker is essentially testing how much margin it can sacrifice to defend market share in Europe while watching patent walls crumble in emerging markets.

Regulators in Brazil gave the green light to Ozivy, a Semaglutide analogue from local manufacturer EMS, marking the country’s first injectable competitor to Ozempic since the original patent lapsed in March. EMS plans to price the drug roughly 30% below Ozempic and launch within 30 days, initially producing 350,000 pre-filled pens across three doses. The company aims to sell 1.2 million units in the first year, targeting more than 500 million Reais in revenue. The blow is significant because Brazil is a fast-growing market for diabetes and weight-loss treatments — and cheaper copies can shift volume quickly, even if the U.S. and Europe remain better protected for now.

Portugal tells a different story, but the underlying theme is the same: pricing pressure. Starting June 1, 2026, Novo Nordisk will cut prices on the two highest injectable doses of Wegovy by 19%. The 1.7 mg dose drops from €214.26 to €173.98, and the 2.4 mg dose falls from €244.80 to €198.53. Because Portugal does not publicly reimburse obesity drugs, the company hopes lower out-of-pocket costs will improve treatment persistence and open the door to longer-term therapy. It is a targeted experiment in balancing volume growth with profitability — a tightrope the market has been watching for months.

That balancing act is already visible in the first-quarter numbers. Group net revenue came in at 96.823 billion Danish kroner, with adjusted operating profit at 32.858 billion kroner — well above the consensus estimate of 28.74 billion. Yet on an adjusted, currency-adjusted basis, revenue fell 4% and operating profit dropped 6%. In the U.S., adjusted sales declined 11% on a currency-neutral basis, while international operations grew 6%, driven by higher Wegovy volumes. The company now expects full-year 2026 currency-adjusted growth of minus 4% to minus 12% for both revenue and operating profit, a corridor it recently narrowed but kept firmly in negative territory.

The share price reflects the uncertainty. After closing at €39.05 on Friday, the stock was up 1.05% over seven days and had gained 13.06% over the past month. But year-to-date it remains down 12.59%, and the 12-month decline stands at 38.58%. Technical signals are mixed: the stock sits above its 50-day moving average but 6.89% below the 200-day line, and the RSI of 71.6 points to near-term overbought conditions.

Patent erosion outside the core markets is accelerating. India saw Semaglutide generics launch in March, prompting Novo Nordisk to cut prices there. Canada has also approved copycat products. The patent cliff now affects India, China, Brazil, Turkey, South Africa, and Canada — countries that represent a huge share of the global population and future demand for obesity and diabetes care. While the U.S. and Europe remain insulated for several more years, the gap between protected premium markets and fast-opening lower-price regions is widening.

Analysts are cautious. Deutsche Bank’s Emmanuel Papadakis rates the stock at Neutral with a target of 290 kroner. Jefferies’ Michael Leuchten also stays at Neutral, with a target of 270 kroner. Among 19 houses, 13 carry a Hold or Neutral recommendation. The seven U.S. banks — including Bernstein, Goldman Sachs, and Morgan Stanley — average a target of 247 kroner and are unanimously on Hold or Sell. The caution stems not from a lack of faith in the pipeline but from pricing headwinds in the U.S. and limited visibility on CagriSema and oral Wegovy.

On the pipeline front, there is a bright spot. The European Medicines Agency’s committee issued a positive opinion on May 21 for a change to the marketing authorization for Wegovy tablets, covering 1.5 mg, 4 mg, 9 mg, and 25 mg strengths. The first oral Wegovy launch outside the U.S. is expected in the second half of 2026, pending regulatory approvals. Novo Nordisk is clearly working to broaden the Wegovy platform into a more convenient form, even as it adjusts pricing on the injectable version in select markets.

Meanwhile, the company continues to return capital to shareholders. The 2026 buyback program runs up to 15 billion kroner, with a tranche of up to 11.2 billion kroner active from May 6, 2026, to February 1, 2027. As of May 22, Novo Nordisk had bought back 17.05 million B-shares at an average price of 262.22 kroner apiece, totalling about 4.47 billion kroner. Buybacks can support the stock technically, but they do not resolve the core conflict: can pipeline progress and pricing discipline offset the loss of patent protection in key international markets?

Investors will get two major signposts soon. On June 7, Novo Nordisk presents its R&D strategy at the ADA 2026 conference, and on August 5 it reports first-half results. Those dates will show whether the company can counter the rising generic tide with fresh data and credible targets — or whether the margin squeeze is only just beginning.